ArticleThe Pan African medical journal2021
Prevalence and correlates of hypertension in HIV-positive adults from the Livingstone Central Hospital, Zambia.
Article in The Pan African medical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Prevalence and determinants of poor outcome in patients with chronic kidney disease in low-income countries in sub-Saharan Africa: a systematic review.The Pan African medical journal · 2026Pooled it
- Burden and Challenges of Managing Hypertension in People Living with Human Immunodeficiency Virus (HIV) Infection in Sub-Saharan Africa: A Mixed Systematic Review and Meta-Analysis.International journal of public health · 2025Pooled it
- Hypertension among people living with human immunodeficiency virus in sub-Saharan Africa: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Hypertension and blood pressure changes with dolutegravir or comparator antiretroviral therapy in randomized trials through 96 weeks.The Journal of antimicrobial chemotherapy · 2025Trial
- Article
- Incidence of hypertension and factors associated with blood pressure control among older adults living with HIV in Western Kenya: a retrospective cohort study.BMC cardiovascular disorders · 2026Article
- Key determinants of integrated health service delivery: lessons from a pilot study on HIV and non-communicable disease integration in Zambia.BMC health services research · 2026Article
- Clinical and Echocardiographic Characteristics Associated with Hypertension in a Cohort of People Living with and without HIV.medRxiv : the preprint server for health sciences · 2026Article
- Novel Insights into Salt-Sensitivity of Blood Pressure in African Adults with and without HIV: Comprehensive Inflammatory, renal and Cardiometabolic Profiling in a Zambian Cohort.medRxiv : the preprint server for health sciences · 2025Article
- The Prevalence and Predictors of Hypertension and Albuminuria in People with HIV (PWHIV)-Real-World Greek Data.Life (Basel, Switzerland) · 2025Article
- Hypertension among people living with HIV receiving dolutegravir-based antiretroviral therapy in ethiopia: a cross-sectional study.Scientific reports · 2025Article
- Prevalence of Hypertension and Its Associated Factors Among Adult People Living with HIV/AIDS at Anti-Retroviral Treatment (ART) Centers in Mumbai, India.HIV/AIDS (Auckland, N.Z.) · 2025Article
- Association of Integrase Strand Transfer Inhibitor-Based Antiretroviral Therapy With Blood Pressure and Sustained Hypertension in People With Human Immunodeficiency Virus.American journal of hypertension · 2024Article
- HIV-Associated Hypertension: Risks, Mechanisms, and Knowledge Gaps.Circulation research · 2024Review
- Evolving mechanisms and presentations of cardiovascular disease in people with HIV: implications for management.Clinical microbiology reviews · 2024Review
- Hypertension Among Cohort of Persons With Human Immunodeficiency Virus Initiated on a Dolutegravir-Based Antiretroviral Regimen in Ghana.Open forum infectious diseases · 2024Article
- Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study.Journal of the International AIDS Society · 2024Article
- Hypertension among persons living with HIV/AIDS and its association with HIV-related health factors.AIDS research and therapy · 2024Article
- Article
- Comorbidity and concomitant medication use in an integrase strand transfer inhibitor naïve cohort on first-line dolutegravir-based antiretroviral therapy.The Pan African medical journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHIV-infection and treatment with antiretroviral therapy (ART) are risk factors for the development of hypertension, which is more prevalent in people living with HIV compared with the general population. Although there is a shift to Integrase Strand Transfer Inhibitor (INSTI)-based ART across the sub-Saharan Africa, there is limited information with regard to INSTIs and hypertension association in this region, making this, a critical question to address. Hence, the study aimed to determine the relationship between hypertension and ART regimen in people living with HIV.
methodsthis was a cross-sectional study conducted at the Livingstone Central Hospital, southern province of Zambia. This study utilized programmatic data. Demographic and clinical data of 348 persons living with HIV who had been on ART for more than 2 years was abstracted in the adult ART database registry. Descriptive and inferential statistics were used for analyses of data.
resultsprevalence of hypertension was 18.4% (n=64). Hypertensives were older than normotensives with median (interquartile range) age of 55 (49, 61) and 46 (41, 52), respectively. At multivariate analysis, age (aOR: 1.07, 95% CI 1.04-1.11; p = 0.001) and body mass index (aOR: 1.10, 95% CI 1.04-1.16; p = 0.002) were positively associated with hypertension. Participants on dolutegravir based regimen were 2 times (aOR: 2.44, 95% CI 1.22-4.86; p = 0.01) more likely to be hypertensive compared to those on non-nucleoside reverse transcriptase inhibitors (efavirenz or nevirapine).
conclusionwe confirm that increasing age, body mass index (BMI) and use of dolutegravir are risk factors for hypertension. Close monitoring for persons with HIV with these known risk factors is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.